Flavoxate Pregnancy and Breastfeeding Warnings
Flavoxate is also known as: Urispas
Medically reviewed on September 4, 2017
Flavoxate Pregnancy Warnings
Animal studies have failed to reveal evidence of impaired fertility and fetal harm. There are no controlled data in human pregnancy.
US FDA pregnancy category B: Animal reproduction studies have failed to demonstrate a risk to the fetus and there are no adequate and well-controlled studies in pregnant women.
Use is recommended only if clearly needed.
US FDA pregnancy category: B
Flavoxate Breastfeeding Warnings
Caution is recommended.
Excreted into human milk: Unknown
Excreted into animal milk: Data not available
Comments: During long-term use, observe the breastfeeding infant for signs of decreased lactation (e.g., insatiety, poor weight gain).
References for pregnancy information
- "Product Information. FlavoxATE Hydrochloride (flavoxATE (flavoxate))." PuraCap Pharmaceutical, South Plainfield, NJ.
- MHRA. Medicines and Health Regulatory Agency "MHRA Drug Safety Update. Available from: URL: http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate."
References for breastfeeding information
- MHRA. Medicines and Health Regulatory Agency "MHRA Drug Safety Update. Available from: URL: http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate."
- "Product Information. FlavoxATE Hydrochloride (flavoxATE (flavoxate))." PuraCap Pharmaceutical, South Plainfield, NJ.
- United States National Library of Medicine "Toxnet. Toxicology Data Network. Available from: URL: http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?LACT." ([cited 2013 -]):
See Also...
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
